{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000032","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.064031+00:00","generated_at":"2026-05-31T23:54:47.119082+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexicon amends Oxford loan: interest-only period to May 2027, maturity to March 2029","bullets":["Amortization date extended to May 1, 2027; maturity date extended to March 1, 2029.","Final payment percentage increased from prior amount to 7.00% of outstanding principal.","New financial covenant: minimum cash at 50% of outstanding Term Loans through June 30, 2026.","Minimum trailing 6-month net product revenue tied to sNDA approval of sotagliflozin in CKD by March 31, 2025.","Amendment fee paid; existing loan agreement continues in full force except as amended."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000032","json":"https://secwatch.observer/filing/0001062822-24-000032.json","markdown":"https://secwatch.observer/filing/0001062822-24-000032.md","text":"https://secwatch.observer/filing/0001062822-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000032/0001062822-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000032/lxrx-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:54:47.119082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}